Combined intravenous and endovascular treatment versus primary mechanical thrombectomy. The Italian Registry of Endovascular Treatment in Acute Stroke by Casetta, I. et al.
Page Proof Instructions and Queries
Publishing
Journal Title: International Journal of Stroke (WSO)
Article Number: 851279
Thank you for choosing to publish with us. This is your final opportunity to ensure your article will be accurate at publication.
Please review your proof carefully and respond to the queries using the circled tools in the image below, which are available
by clicking ‘‘Comment’’ from the right-side menu in Adobe Reader DC.*
Please use only the tools circled in the image, as edits via other tools/methods can be lost during file conversion. For comments,
questions, or formatting requests, please use . Please do not use comment bubbles/sticky notes .
Comment
*If you do not see these tools, please ensure you have opened this file with Adobe Reader DC, available for free at
get.adobe.com/reader or by going to Help > Check for Updates within other versions of Reader. For more detailed
instructions, please see us.sagepub.com/ReaderXProofs.
No. Query
Please note, only ORCID iDs validated prior to acceptance will be authorized for publication; we are unable to add
or amend ORCID iDs at this stage.
Please confirm that all author information, including names, affiliations, sequence, and contact details, is correct.
Please review the entire document for typographical errors, mathematical errors, and any other necessary
corrections; check headings, tables, and figures.
Please confirm that the Funding and Conflict of Interest statements are accurate.
Please ensure that you have obtained and enclosed all necessary permissions for the reproduction of artistic works,
(e.g. illustrations, photographs, charts, maps, other visual material, etc.) not owned by yourself. Please refer to your
publishing agreement for further information.
Please note that this proof represents your final opportunity to review your article prior to publication, so please do
send all of your changes now.
AQ: 1 Please confirm that the authors are correctly linked to their corresponding affiliations. Also please provide the city
and country names where missing.
AQ: 2 Please confirm the footnote ‘*For details on The Italian Registry of Endovascular Treatment in. . .’ is correct as set.
AQ: 3 Is it ‘‘National Institute of Health Stroke Scale’’ or ‘‘National Institutes of Health Stroke Scale’’? Please correct it
as needed throughout the article.
AQ: 4 Please update details for the references 13 and 22.
AQ: 5 Please insert the year for the reference 29.
AQ: 6 Please provide significance of bold values in Table 1.
AQ: 7 Please check that all the values in Table 1 are set correctly.
AQ: 8 Please define abbreviation TIA in Table 1.
Research
Combined intravenous and endovascular
treatment versus primary mechanical
thrombectomy. The Italian Registry of
Endovascular Treatment in Acute Stroke
Ilaria Casetta1 , Giovanni Pracucci2, Andrea Saletti3,
Valentina Saia4, Marina Padroni5, Alessandro De Vito5,
Domenico Inzitari2, Andrea Zini6, Stefano Vallone7,
Mauro Bergui8, Paolo Cerrato9,10, Sandra Bracco11,
Rossana Tassi12, Roberto Gandini13, Fabrizio Sallustio14,
Mariangela Piano2,15, Cristina Motto16, Paolino La Spina17,
Sergio L Vinci18, Francesco Causin19, Claudio Baracchini20,
Roberto Gasparotti21, Mauro Magoni22, Lucio Castellan23,
Carlo Serrati24, Salvatore Mangiafico25, Danilo Toni26 and
on behalf of the The Italian Registry of Endovascular
Treatment in Acute Stroke
Abstract
Background: Whether mechanical thrombectomy alone may achieve better or at least equal clinical outcome than
mechanical thrombectomy combined with intravenous thrombolysis is a matter of debate.
Methods: From the Italian Registry of Endovascular Stroke Treatment, we extracted all cases treated with intravenous
thrombolysis followed by mechanical thrombectomy or with primary mechanical thrombectomy for anterior circulation
stroke due to proximal vessel occlusion. We included only patients who would have qualified for intravenous thromb-
olysis. We compared outcomes of the two groups by using multivariate regression analysis and propensity score method.
Results: We included 1148 patients, treated with combined intravenous thrombolysis and mechanical thrombectomy
therapy (n¼ 635; 55.3%), or with mechanical thrombectomy alone (n¼ 513; 44.7%). Demographic and baseline clinical
characteristics did not differ between the two groups, except for a shorter onset to groin puncture time (p< 0.05) in the
mechanical thrombectomy group. A shift in the 90-day modified Rankin Scale distributions toward a better outcome was
found in favor of the combined treatment (adjusted common odds ratio ¼ 1.3; 95% confidence interval: 1.04–1.66).
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Multivariate analyses on binary outcome show that subjects who underwent combined treatment had higher probability
to survive with modified Rankin Scale 0–3 (odds ratio¼ 1.42; 95% confidence interval: 1.04–1.95) and lower case fatality
rate (odds ratio¼ 0.6; 95% confidence interval: 0.44–0.9). Hemorrhagic transformation did not differ between the two
groups.
Conclusion: These data seem to indicate that combined intravenous thrombolysis and mechanical thrombectomy could
be associated with lower probability of death or severe dependency after three months from stroke due to large vessel
occlusion, supporting the current guidelines of treating eligible patients with intravenous thrombolysis before mechanical
thrombectomy.
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Introduction
Several randomized controlled trials1–7 demonstrated
the efficacy of mechanical thrombectomy (MT) in
patients with acute ischemic stroke caused by a prox-
imal intracranial occlusion in the anterior circulation.
A meta-analysis confirmed that, compared with intra-
venous thrombolysis (IVT) alone, endovascular
thrombectomy as add-on to IVT increased the prob-
ability of good outcome, without increasing the risk
of symptomatic hemorrhage, after large vessel ischemic
stroke in the anterior circulation.8 Therefore, current
guidelines recommend to treat eligible patients with
IVT before MT. However, the added value of IVT
treatment before MT is still under debate.
Observational retrospective analyses gave conflicting
results: while some of them suggested a benefit of
IVT pretreatment,9–13 in terms of higher rate of reca-
nalization, shorter duration of the endovascular pro-
cedure, lower number of passes of the thrombectomy
device per patient, or better clinical outcome, others
did not find significant differences between the two
approaches.14–22
A pooled analysis23 of the STAR24 and SWIFT25
trials suggested that treatment with IVT before MT
does not add any clinical benefit as compared to MT
alone. Conversely, two meta-analyses carried out on
subgroups of patients included in the available rando-
mized clinical trials,26 and on available observational
and randomized studies27 showed that bridging therapy
leads to a lower probability of death or serious disabil-
ity as compared to MT alone.
However, a significant proportion of patients
included in the above studies and treated with MT
alone, were not eligible for IVT, thus representing a
group of patient inherently different from those who
qualified for IVT.
The aim of this study was to compare the outcome of
patients with acute ischemic stroke due to proximal
intracranial artery occlusion in the anterior cerebral
circulation, eligible for IVT according to current guide-
lines, treated with combined therapy with those who
underwent primary MT, included in the Italian
Registry of Endovascular Stroke Treatments.28
Materials and methods
We retrieved data from The Italian Registry of
Endovascular Stroke Treatments,28 a multicenter, pro-
spective, observational internet-based registry (http://
www.registroendovascolare.it). The purposes, organ-
ization, and structure of the Registry were described
in more details elsewhere.28
All patients who underwent endovascular treatment
in the participating centers were consecutively rec-
orded: for each patient, demographics, stroke risk fac-
tors, personal history, stroke severity, laboratory
findings, any contraindication for IVT (and the reasons
for exclusion from IVT), time from symptom onset to
diagnosis and treatment, baseline neuroimaging data,
treatment details, and outcome information were pro-
spectively collected.
Patients and interventions
In the present analysis, we included all cases treated
either with IVT followed by MT (IVT-MT) or with
MT alone for anterior circulation stroke due to prox-
imal vessel occlusion (internal carotid artery, and M1
or M2 segment of the middle cerebral artery). We
restricted the analysis to patients who would have
been eligible for IVT, according to the current guide-
lines.29 Patients with IVT contraindications,29 posterior
circulation stroke, treated with intra-arterial thromb-
olysis, or patients who ultimately did not undergo any
endovascular treatment were excluded. We limited the
analysis to patients treated between 2011 and 2015
because of the widespread use of next generation
devices for thrombectomy since 2011. Moreover, in
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2015, new recommendations for IVT in acute stroke
were released to relax some of the original exclusion
criteria that had proven to be unnecessarily restrictive
in real-world clinical practice. These amendments
overcame IVT undertreatment due to strict exclusion
criteria.29 In particular, mild deficit or rapid improve-
ment of symptoms, clinically severe stroke, seizure at
onset, stroke present upon awakening, history of stroke
and concomitant diabetes, history of stroke in the last
three months, serum glucose levels <50 or >400mg/dl,
severe arterial hypertension and aggressive treatment
required to reduce the blood pressure (BP) to the
accepted limits (systolic BP< 185, and diastolic
BP< 110mmHg), arterial aneurysms or arteriovenous
malformations, history of central nervous system dis-
eases, and major surgery or severe trauma <3 months
are no longer considered absolute exclusion criteria.29
Many patients who had not been considered eligible for
IVT on the basis of previous guidelines or of their too
restrictive interpretation would have been treated
according to the new recommendations.
Thus, we could include a large sample of patients
qualified for IVT, who did not undergo this treatment.
IVT was administered according to the national
guidelines within 4.5 h from symptom onset at
the usual dosage (0.9mg/kg body weight, maximum
90mg).
Endovascular treatment was performed with or
without previous IVT within 6 h of symptom onset
using stent retrievers and/or aspiration devices.
The final treatment decision was left at the discretion
of the neurologist and neurointerventionalist on duty.
All patients underwent CT scan 24 h after therapy or
in case of clinical worsening.
Clinical evaluation and outcome measures
Stroke severity was evaluated by the National Institute
of Health Stroke Scale (NIHSS), at baseline, after the
end of therapeutic procedure and after seven days.
[AQ3]
Hemorrhagic transformations were classified accord-
ing to the ECASS II criteria.30
Symptomatic intracranial hemorrhage (SICH) was
defined as any intracranial hemorrhage associated
with 4 points increase in the NIHSS or leading to
death.30 The primary outcome measure for this study
was the mRS score at 90 days (range 5 days), as
assessed by a local trained neurologist unaware of the
treatment given through in-person visit, or through a
phone standardized interview when a face to face
assessment was not possible.
For efficacy measures, arterial recanalization was
rated according to the thrombolysis in cerebral infarc-
tion (TICI) score.31 Successful reperfusion was defined
as TICI score 2b or 3. Number of stentriever passes,
thrombotic fragmentation, and distal embolization
were also recorded.
SICH, procedural adverse events (subarachnoid
hemorrhage and vessel dissection), and death rate
were considered as safety measures. Need for ethical
approval or patient consent for participation in the
Italian Registry of Endovascular Treatment in Acute
Stroke varied among participating hospitals. Ethical
approval and patient consent were obtained where
required.
Statistical analysis
Data were presented as absolute number, percentages,
mean standard deviation or median and interquartile
range (IQR) as appropriate. Dichotomous variables
were compared using the chi squared test, and continu-
ous variables were compared by Student’s t-test or
Mann–Whitney U test as appropriate on the basis of
data distribution. The functional outcome was evalu-
ated with ordinal logistic regression, taking the whole
range of mRS into account as dependent variable to
obtain a common odds ratio (OR, and 95% confidence
interval (CI)) for a shift in the direction of a better
outcome on the mRS. A multivariate model was
planned to adjust for age, sex, history of diabetes,
atrial fibrillation, hypertension, previous stroke or tran-
sient ischemic attack in the previous three months, the
presence of carotid stenosis >70%, baseline NIHSS
score, wake-up stroke, onset to door time, onset to
groin puncture time, site of occlusion, and ASPECTS
score. A second model was run to add TICI score as an
additional covariate. The mRS at 90 days was also
treated as dichotomous variable comparing the propor-
tion of patients surviving with mRS 0–1, mRS 0–2, or
mRS 0–3 between the two treatment groups. All dichot-
omous variables were evaluated by using a logistic
regression analysis and adjusting for the above men-
tioned covariates.
Given the observational nature of this study, to
address the imbalance of baseline characteristics
between the two treatment groups, we adopted a pro-
pensity score (PS) analysis with an inverse probability
of treatment weighting (IPW) method.32–34 The individ-
ual PS was calculated by logistic regression analysis
using treatment as dependent variables and adding, as
covariates sex, age, and all additional explanatory vari-
ables that differed between the two groups, or that
could influence patient assignment or outcome (age,
sex, history of hypertension, diabetes, prior stroke or
transient ischemic attack, atrial fibrillation, use of oral
anticoagulants, known carotid stenosis >70%, wake-
up stroke, time interval from symptom onset to hos-
pital arrival, and site of arterial occlusion). This PS was
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used in the subsequent analyses with the IPW method,
where subjects who received IVT and MT were
weighted by an inverse of their PS whereas those
who received MT alone were weighted by an inverse
of 1  PS.33,34
The IPW created a synthetic sample in which the
distribution of measured baseline covariates is inde-
pendent of treatment assignment. To estimate treat-
ment effect, ordinal and logistic regression models
were built to derive IPW ORs.
A two-sided p value <0.05 was considered significant
for all tests. Analysis was performed using SPSS statis-
tical package version 23, and R release 3.1.2.
Results
We included 1148 consecutive patients treated with
combination of IVT and MT (n¼ 635; 55.3%), or
with MT alone (n¼ 513; 44.7%), in 13 Italian centers
from 2011 through 2015.
Most patients (1043) were directly referred to an
endovascular-capable center (ECC), while 105 were
sent to the comprehensive stroke center from a hospital
capable of assessing the patients and delivering at least
IVT: of these latter, 63 underwent combined treatment,
and 42 primary endovascular treatment.
The reasons not to treat patients with IVT were
exclusion criteria recommended by previous guidelines
(and in the summary of product characteristics of
Actilyse) and no longer reported in the current ones
(331 patients). In many circumstances (152 patients),
the treating team decided against IVT thrombolysis
and performed direct endovascular treatment because
of a time of arrival judged to be too close to the 4.5 h
time window (32 patients), concerns regarding the
coagulation status or borderline INR, comorbidities
such as renal dysfunction or malignancies, leukoaraio-
sis on CT scan, advanced age, high-burden clot, or
proximal clot location. Thirty patients underwent pri-
mary endovascular treatment in the setting of a rando-
mized clinical trial.
Demographic data, risk factors distribution, and
baseline characteristics were not significantly different
between the two groups (Table 1).
Time from symptoms onset to first hospital arrival
was similar in the two groups (Table 1) as was the
median time from onset to ECC arrival (95min, IQR
59–143.2 for combined therapy patients, and 96min,
IQR 60–150 for MT patients; p¼ 0.7), and the time
from onset to CT scan. Patients who underwent com-
bined treatment had a significantly (p< 0.05) longer
time from onset to groin puncture (230min, IQR
185–275 versus 210min, IQR 170–270). Median onset
to end of treatment time was slightly higher in IVT-MT
patients (315min, IQR 258–362.5) than in MT patients
(300min, IQR 252.75–360), without statistically signifi-
cant differences (p¼ 0.15). Median time from groin
puncture to the end of the procedure was shorter
(p< 0.05) for patients who underwent combined treat-
ment (55min, IQR 27.5–90) than for MT patients
(60min, IQR 34.5–90).
The distribution by site of arterial occlusion was
similar in the two groups (Table 1). After adjustment
by IPW, none of the clinical or procedural characteris-
tics remained significantly different between the two
groups (Table 1).
The stacked bar graph (Figure 1) shows 90-day clin-
ical outcome (mRS) for each treatment arm.
A shift in the 90-day mRS distributions toward a
better outcome was found in favor of the combined
IVTþMT treatment. The common unadjusted OR
was 1.45 (95% CI: 1.18–1.78), and it was 1.3 (95%
CI: 1.04–1.66), when adjusted to the above possible
confounders.
Multivariate analysis (Figure 2) showed that the pro-
portion of people surviving with mRS 0–3 was signifi-
cantly higher in the combined treatment group
(adjusted OR¼ 1.42; 95% CI: 1.04–1.95), while the
risk of death or very unfavorable outcome (mRS 5–6)
was significantly lower in the same arm (adjusted
OR¼ 0.62; 95% CI: 0.45–0.84). The 90-day case fatal-
ity rate was lower in patients treated with combined
therapy than in those who underwent primary MT
(adjusted OR¼ 0.6; 95% CI: 0.44–0.9). These results
retained statistical significance after adjustment for
TICI 2b–3 in the multivariate model.
The recanalization rate (TICI 2b–3) was higher in
the combined treatment arm (71% versus 66%).
Complete recanalization (TICI 3) was achieved in
55% of patients in the combined treatment group and
in 49% of patients treated with primary endovascular
thrombectomy. These differences lost statistical signifi-
cance after multivariate comparisons (Figure 2). No
differences were found regarding hemorrhagic trans-
formation or procedure complications.
The PS analysis yielded the same results regarding
clinical outcomes (Figure 3).
Discussion
The results of this study suggest that IVT treatment
before MT procedure can lead to a better outcome,
without affecting safety in patients with anterior circu-
lation stroke due to large artery occlusion, and eligible
to IVT. There was a significant shift in the distribution
of the primary-outcome scores in favor of the combined
intervention. Moreover, patients treated with combined
therapy had significantly lower rates of death/severe
disability as compared with patients undergoing only
MT. These results are consistent with those reported
International Journal of Stroke, 0(0)
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Table 1. Demographic and clinical characteristics of MT and IVTþMT patients. [AQ6]
Original sample IPW samplea
IVTþMT MT p value IVTþMT MT p value
Age (years): mean (SD) 67.6 (14.6) 68.8 (13.1) 0.18 68.3 (13.9) 68.5 (13) 0.8
Sex (women) 50.7 51.1 0.9 52.6 52.2 0.97
Hypertension 65.8 63.4 0.43 66.1 66.8 0.84
Atrial fibrillation 27.8 32.3 0.13 30 34.6 0.2
Diabetes mellitus 13 17 0.08 15.4 18.1 0.1
Dyslipidemia 26.2 28.8 0.37 27.1 29.3 0.56
Smoke 23.8 18.9 0.06 22.2 19.2 0.38
Previous stroke/TIAb 2.7 6.6 < 0.01 4.4 5.3 0.1
Carotid stenosis> 70% 4.4 5.1 0.6 5.6 6 0.8
NIHSS at entry: median, IQR 18, 14–21 18, 14–22 0.51 18, 14–21 18, 14–22 0.55
Site of vessel occlusion 0.22 0.77
MCA-M1 48.8 44.8 0.18 49.9 48.4 0.68
MCA-M2 14.2 12.5 0.4 14.2 12.1 0.43
Carotid tandem occlusion 19.1 23.4 0.07 18.2 19.8 0.63
Carotid T occlusion 18 19.3 0.56 17.7 19.8 0.95
Process times : median, IQR
Onset to first
hospital admission
73, 46–111 80, 48–128.5 0.08 73, 46–101 80.4,
54.4–134.3
0.32




























ECC: endovascular-capable stroke center; IQR: interquartile range; IVT: intravenous thrombolysis; MCA: middle cerebral artery; MT: mechanical
thrombectomy; NIHSS: National Institute of Health Stroke Scale; TIA: . [AQ8]
Number indicate percentages unless otherwise noted.
aIPW: inverse probability weighting (see text for definition).
bTIA or stroke in the last three months.
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from observational studies9–13,35,36 and available meta-
analyses.26,27 A recent post hoc analysis of the ASTER
trial (Contact Aspiration Versus Stent Retriever for
Successful Revascularization) showed a lower 90-day
mortality rate in the IVTþMT group than after
MT alone, and a better functional outcome, recanaliza-
tion rate, and reduced mortality in a subgroup of
patients.37
Figure 2. Outcome data: comparison between IVTþMT and in MT patients. *Common OR for a shift toward better outcome.
**AdjOR: ORs were adjusted for age, sex, history of diabetes, atrial fibrillation, hypertension, previous stroke or transient
ischemic attack in the previous three months, the presence of carotid stenosis> 70%, baseline NIHSS score, baseline ASPECTS
score, onset to ECC arrival time, onset to groin puncture time, site of occlusion. PH1: parenchymal hematoma occupying less than
30% of the infarct zone, with some mass effect; PH2: parenchymal hematoma occupying less than 30% of the infarct zone, with
significant mass effect; SICH: symptomatic hemorrhagic transformation.
Figure 1. Three-month mRS in IVTþMT versus MT patients.
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It has been suggested that preceding IVT thromboly-
sis could facilitate and shorten the endovascular
procedure, by partially lysing the clot, thus making
easier its detachment from the vessel wall.
Recanalization of distal thrombi that are not accessible
to endovascular devices could be another, at least par-
tial, explanation.
In this study, while the onset to groin puncture time
was significantly longer in combined therapy patients,
the onset to end of procedure time was similar in the
two groups, because of the shorter duration of the pro-
cedure with fewer stentriever passes.
Moreover, the recanalization rate was higher in
patients receiving combined treatment as compared
with subjects who underwent primary MT, and
this could at least in part explain the differences in clin-
ical outcome between the two groups although the
association between combined treatment and better
functional outcome retained statistical significance
after adjustment for TICI 2b–3 in the multivariate
model.
As in other similar studies,14–18,21,22 we found that
the proportion of patients with hemorrhagic complica-
tions was higher in the combined treatment group
although the difference was not statistically significant
due to the small number of events in both group.
However, the combined treatment could increase the
chances of acceptable recovery and reduce mortality.
The benefit of combined therapy versus MT alone is
still a matter of debate. Many studies, in fact, did not
reveal any difference between the two treatments.14–22
On the whole the available studies are based on
small samples of patients, the larger study being the
Catalonia analysis, including 1166 patients.18 On the
basis of data from a recent meta-analysis,26 assuming
an alpha of 0.05 and beta of 0.2, a total sample of 408
patients would be needed to detect a 12% absolute dif-
ference in 90-day death or severe dependency, and 962
patients to detect a 9.7% absolute difference in func-
tional independence at three months. Thus, most of the
above studies have a low statistical power, and the fail-
ure to reject the null hypothesis could be due to a type
II error due to the small sample size. On the other hand,
some studies reporting negative results showed a non-
significant trend toward a better outcome in patients
treated with bridging therapy.14,16,19,20
All but five16,18,20,21,36 studies did not account for
their observational nonrandomized nature, which car-
ries potential selection biases resulting from assignment
to bridging treatment or primary endovascular thromb-
ectomy on the basis of pretreatment baseline data
rather than randomization.
Moreover, the main shortcoming of most of the
above comparisons was to include both IVT eligible
and not IVT eligible patients in the MT group or to
compare eligible IVT patients treated with combined
Figure 3. Outcome data: comparison between IVTþMT and in MT patients. Multivariate analysis using inverse probability of
treatment weight. *Common OR for a shift toward better outcome. **AdjOR: ORs were adjusted for age, sex, history of
diabetes, atrial fibrillation, hypertension, previous stroke or transient ischemic attack in the previous three months, the presence
of carotid stenosis> 70%, baseline NIHSS score, baseline ASPECTS score, onset to ECC arrival time, onset to groin puncture
time, site of occlusion. **PSOR: propensity score (PS) analysis with inverse probability of treatment weighting method. PH1:
parenchymal hematoma occupying less than 30% of the infarct zone, with some mass effect; PH2: parenchymal hematoma
occupying over 30% of the infarct zone, with significant mass effect; SICH: symptomatic hemorrhagic transformation.
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therapy to ineligible patients treated with MT alone.
Only four studies, in fact, compared patients who
would have been eligible for IVT.16,17,20,21 These stu-
dies, on the whole did not find significant differences.
We analyzed a large real-world sample of IVT
eligible patients and we could observe a significant
reduction of mortality and serious disability in patients
treated with bridging therapy. These results retained
statistical significance after PS modeling, to account
for the nonrandomized nature of the study.
This study has several limitations: First, a weakness
of the study was the lack of random allocation of
patients to either treatment group: since the therapeutic
option was left to the discretion of the attending phys-
ician, factors that have influenced treatment selection
also could have influenced outcomes, leading to bias.
PS approaches attempt to correct this problem by
ensuring that the treatment groups under study are
balanced with respect to measured covariates, but
they cannot balance unmeasured characteristics and
confounders.
Second, while the onset to door time (as well as the
door to CT scan time) was acceptably short as a result
of strategies implemented in early 2000s for timely
delivery of IVT, the in-hospital process times were
quite long, mostly due to a delay in the CT to groin
puncture time. In should be noted that the enrollment
of the majority of our study population predated the
publication of trials demonstrating the benefit of endo-
vascular recanalization treatment over IVT alone
among patients with acute stroke due to large vessel
occlusions. These trials prompted stroke centers,
including ours, to plan and implement further system
strategies to shorten in-hospital processes (prenotifica-
tion of the neurointerventional team, expediting con-
sent acquisition, and transfer to angiography suite),
to minimize time from qualifying imaging to groin
puncture. On the other hand, the workflow times in
our study did not differ from that reported in some
randomized clinical trials carried out in the same
period (median time from onset to groin puncture:
238min, IQR 180–302; and from onset to reperfusion:
301min, IQR 226–384),38 a remarkable exception being
represented by the SWISS PRIME trial that was
designed to include an intensive program of workflow
acceleration.39
Another limitation is that patients treated with IVT
who had achieved recanalization before MT were not
included in this analysis because their data are not sys-
tematically recorded in the Registry.
It is known that pretreatment with systemic thromb-
olysis in patients with stroke due to large vessel occlu-
sion results in successful reperfusion before the onset of
endovascular procedure in about 10% of cases obviat-
ing the need for additional intervention.40,41
Conclusions
Our results suggest that current practice of administer-
ing IVT thrombolysis in eligible patients eventually fol-
lowed by MT remains the standard approach, although
an increased risk of symptomatic hemorrhage should be
taken into account.
However, evidence can be definitely established only
by a randomized controlled trial.42
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